中文版English

NEWS FEED

New US nod for Merck's nausea and vomiting drug

US regulators have approved a single-dose version of Merck & Co's chemotherapy-associated nausea and vomiting drug Emend.

 

The jab's use has been cleared, in combination with other anti-emetics, for the prevention of delayed nausea and vomiting in adults taking moderately emetogenic chemotherapy (MEC). The decision makes Emend (fosaprepitant dimeglumine) the first intravenous single-dose NK1 receptor antagonist approved in the US for both highly emetogenic chemotherapy (HEC) as well as MEC. Clearance was issued on the back of data from a Phase III study in which a 78.9 percent complete response rate was observed with the Emend regimen compared to 68.5 percent with the active control regime. “Despite significant advances in supportive care, nausea and vomiting has remained a challenge for many cancer patients undergoing moderately emetogenic chemotherapy - and has historically required multi-day antiemetic therapy,” said Stuart Green, who heads clinical research at Merck Research Laboratories. The approval of an expanded indication “means that physicians now have a new single-dose intravenous option, combined with other anti-vomiting medicines, for the prevention of delayed nausea and vomiting in these patients."The pill form of Emend was approved back in 2003.

 

Read more at: http://www.pharmatimes.com/Article/16-02-05/New_US_nod_for_Merck_s_nausea_and_vomiting_drug.aspx#ixzz409X2mqLx


Tag:  Aprepitant
PRODUCT SEARCH

EVENTS

What We Can Do

SENOVA Main Products Includes ~ 

1. Anti-Cancer (Oncology) Series 

2. Anti-Infection Series 
3. Anti-Diabetes Series 
4.Pepties Series and other series

SENOVA Service Includes ~ 

1. Documents for Registration
2. Pre-Audit Service
3. GMP regulation consultant
 

Our Corporate Philosophy -

 

Target To – become qualified and reliable APIs/Advanced Intermediates/Key Starting Materials(KSM) for pharmaceuticals manufacturers, drug R&D centers, universities and colleges worldwide
 

Qualification & Capability – we have GLP labs and GMP facilities to supplying new APIs (Active Pharmaceutical Ingredients) and related intermediates with mature technology from lab scale to bulk scale, and secure the whole manufacturing process is under control as international regulation.

 

Some Links
Contact Us
Senova Technology Company Limited
Address: 309# in Building 3 of North Area, Dayuan Industry Park, Xili, Nanshan District of Shenzhen
Tel/Fax: +86 - 755 - 8670 3119
Email: sales@senovatech.com